U.S. FDA Pinpoints Culprit In Bad Heparin
This article was originally published in PharmAsia News
Executive Summary
U.S. FDA has evaluated data that provides "a very solid mechanistic link" between patients who have received bolus dosing of contaminated heparin and observed adverse reactions, according to Center for Drug Evaluation and Research Director Janet Woodcock
You may also be interested in...
South Korea Orders Sanofi-Aventis To Recall Contaminated Heparin
TOKYO - South Korea's food and drug protection agency announced it has ordered the local unit of French drug maker Sanofi-Aventis SA to recall its top-selling heparin drug after finding an unspecified amount of impure material in the product
China’s SFDA Rapid Response To Biopharmaceutical-Triggered Deaths Seen As Progress By Industry Observers
BEIJING - In a case that closely parallels FDA's investigation of the drug heparin, China's State FDA is now examining a biopharmaceutical that triggered severe adverse reactions in seven Chinese patients, six of whom have died
South Korea Orders Sanofi-Aventis To Recall Contaminated Heparin
TOKYO - South Korea's food and drug protection agency announced it has ordered the local unit of French drug maker Sanofi-Aventis SA to recall its top-selling heparin drug after finding an unspecified amount of impure material in the product